Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Entegris, Inc./ATMI, Inc. merger agreement
| February 04, 2014 • Antitrust Risk-shifting • $1.15 billion (including $300 million in cash acquired and the net cash proceeds from the sale of Target's Life Sciences business of $170 million). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.